Last reviewed · How we verify
Risk of symptomatic peptic ulcer
Risk of symptomatic peptic ulcer is a Small molecule drug developed by AstraZeneca. It is currently in Phase 2 development.
At a glance
| Generic name | Risk of symptomatic peptic ulcer |
|---|---|
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy (PHASE4)
- Risk of Uncomplicated Peptic Ulcer in the General Population
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Risk of symptomatic peptic ulcer CI brief — competitive landscape report
- Risk of symptomatic peptic ulcer updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Risk of symptomatic peptic ulcer
What is Risk of symptomatic peptic ulcer?
Risk of symptomatic peptic ulcer is a Small molecule drug developed by AstraZeneca.
Who makes Risk of symptomatic peptic ulcer?
Risk of symptomatic peptic ulcer is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).
What development phase is Risk of symptomatic peptic ulcer in?
Risk of symptomatic peptic ulcer is in Phase 2.
Related
- Manufacturer: AstraZeneca — full pipeline
- Compare: Risk of symptomatic peptic ulcer vs similar drugs
- Pricing: Risk of symptomatic peptic ulcer cost, discount & access